Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
Status:
Recruiting
Trial end date:
2026-07-11
Target enrollment:
Participant gender:
Summary
This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin
(GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be
administered to patients with multiple myeloma prior to and following high-dose melphalan and
autologous stem cell transplantation (ASCT), in conjunction with standard lenalidomide
maintenance. We hypothesize that administration of belantamab mafodotin as part of autologous
stem cell transplant consolidation and maintenance will be safe, well tolerated, and
efficacious in comparison to historical data.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania